Api4000 mass spectrometer

Manufactured by Shimadzu

The API4000 is a mass spectrometer produced by Shimadzu. It is designed to accurately measure the mass-to-charge ratio of ionized molecules, providing precise analytical data for various applications.

Automatically generated - may contain errors

Lab products found in correlation

Pal autosampler, by Shimadzu (1 mentions) Lc 10ad hplc, by Shimadzu (1 mentions) Prominence uflc system, by Shimadzu (1 mentions) Zorbax hilic plus column, by Agilent Technologies (1 mentions)

Close spelling variants of this product

API4000 Qtrap mass spectrometer Spectrometers

2 protocols using api4000 mass spectrometer

In Vitro Metabolic Stability Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

Metabolic stability was determined as described in reference 14 (link). CD101 (1 μM) was incubated with liver microsomes and hepatocytes from Sprague-Dawley rats, cynomolgus monkeys, and humans or hepatocytes only from dogs with appropriate cofactors for up to 2 h at 37°C. Following incubation, samples were quenched with ice-cold methanol or acetonitrile (ACN), containing an appropriate internal standard and centrifuged to remove precipitated protein, and the supernatants were analyzed to quantitate the remaining parent. Samples from in vitro experiments were analyzed either by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using an Agilent 6410 mass spectrometer coupled with an Agilent 1200 high-performance liquid chromatography (HPLC) device and a CTC PAL autosampler (microsomes) or an Applied Biosystems API4000 mass spectrometer coupled with a Shimadzu LC10 AD HPLC and a CTC PAL autosampler (hepatocytes). Two control agents (warfarin and verapamil) were analyzed under similar conditions. Data were converted to the percentage remaining by dividing by the time zero concentration value. Data were fit to a first-order decay model to determine half-life. Intrinsic clearance was calculated from the half-life and the protein concentrations.

Ong V., Hough G., Schlosser M., Bartizal K., Balkovec J.M., James K.D, & Krishnan B.R. (2016). Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. Antimicrobial Agents and Chemotherapy, 60(11), 6872-6879.

+ Open protocol

+ Expand

Quantification of Citrulline by LC-MS/MS

Check if the same lab product or an alternative is used in the 5 most similar protocols

LC-MS/MS analyses were performed on an Applied Biosystems® API4000 Mass Spectrometer (Carlsbad, CA) coupled with a Shimadzu Prominence UFLC system (Shimadzu Corp., Kyoto, Japan). Mobile phases A and B consisted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. LC gradient separation was performed on a Zorbax HILIC Plus column (2.1 × 50 mm, 3.5 μm) (Agilent Technologies Inc., Palo Alto, CA) operated at 40°C, with a flow rate of 0.500 ml/min. The retention time for both citrulline and the internal standard occurred at 2.35 min and the total run time was 5.0 min.
Detection was performed with the Multiple Reaction Monitoring (MRM) mode using the electro-spray ionization (ESI) technique in positive-ion mode with the following transitions: citrulline (m/z 177.1 → 160.2) and d₇-citrulline (m/z 183.0 → 166.0). Mass spectrometry sensitivity was decreased using the ¹³C isotope for citrulline. The other state file parameters used were as follows: spray voltage +5,000 V; temperature 550°C; collision (CAD) gas pressure 6 psi; GS1 pressure 60 psi; GS2 pressure 60 psi; curtain gas 30 psi; collision energy (CE) 20 eV; entrance potential (EP) 10 V and collision cell exit potential (CXP) 12 V.

Bujold K., Hauer-Jensen M., Donini O., Rumage A., Hartman D., Hendrickson H.P., Stamatopoulos J., Naraghi H., Pouliot M., Ascah A., Sebastian M., Pugsley M.K., Wong K, & Authier S. (2016). Citrulline as a Biomarker for Gastrointestinal-Acute Radiation Syndrome: Species Differences and Experimental Condition Effects. Radiation research, 186(1), 71-78.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!